摘要
【目的】探讨肿瘤型M2丙酮酸激酶(TumortypeM2-pyruvatekinase,TUM2-PK)在膀胱癌中的表达及临床意义分析。【方法】采取2009年1月至2012年1月,221例膀胱癌患者和220例健康正常人的血清标本,应用酶联免疫吸附测定法(ELISA)定量检测标本的TUM2-PK水平,研究试验组与对照组,以及病理分型与TUM2-PK关系。【结果】膀胱癌患者血清中TUM2-PK的含量明显高于正常对照组[(39.4±3.5)u/mLvs(7.3±2.1)u/mL(P<0.05)];同时根据膀胱癌病理分级TUM2-PK的含量存在一定差异:T1期(32.1±6.1)u/mL,T2期(34.1±4.3)u/mL,T3期(68.2±5.9)u/mL。T1期膀胱癌与T2期膀胱癌TUM2-PK含量无明显差异,但T3期较T1、T2明显增高。【结论】监测血清中TUM2-PK含量有助于膀胱肿瘤的早期诊断,同时根据TUM2-PK的含量亦可作为监测肿瘤及疾病分级的重要手段之一。
[Objective]To explore the expression of tumor type M2-pyruvate kinase(Tu M2-PK) in bladder cancer and its clinical significance .[Methods] Serum samples of 221 patients with bladder cancer and 220 healthy normal people from Jan .2009 to Jan .2012 were collected .Serum level of Tu M2-PK was detected by ELISA ,and compared between experimental group and control group .The correlation between Tu M2-PK and pathological type was analyzed .[Results]Serum levels of Tu M2-PK in patients with bladder cancer were ob-viously higher than those in control group[(39 .4 ± 3 .5)u/mL vs (7 .3 ± 2 .1)u/mL ,P 〈0 .05)] .There was significant difference in Tu M2-PK level among different pathological stages of bladder cancer .Tu M2-PK lev-els in stage T1 ,T2 and T3 were (32 .1 ± 6 .1)u/mL ,(34 .1 ± 4 .3)u/mL and (68 .2 ± 5 .9)u/mL ,respectively . There was no significant difference in Tu M2-PK level between stage T1 and stage T2 .Compared with stage T1 and T2 ,Tu M2-PK levels in stage T3 were increased obviously .[Conclusion] The monitoring of serum Tu M2-PK is helpful for the early diagnosis of bladder cancer .Meanwhile Tu M2-PK level can be also used as an important means for the monitoring and grading of the tumor .
出处
《医学临床研究》
CAS
2014年第4期644-645,648,共3页
Journal of Clinical Research
基金
黑龙江省卫生厅支撑项目(项目编号:2006137)